258 related articles for article (PubMed ID: 33436648)
21. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway.
Liu B; Liu Y; Zhao L; Pan Y; Shan Y; Li Y; Jia L
Mol Carcinog; 2017 Dec; 56(12):2669-2680. PubMed ID: 28767179
[TBL] [Abstract][Full Text] [Related]
23. VPS33B interacts with NESG1 to suppress cell growth and cisplatin chemoresistance in ovarian cancer.
Ning Y; Zeng Z; Deng Y; Feng W; Huang L; Liu H; Lin J; Zhang C; Fan Y; Liu L
Cancer Sci; 2021 May; 112(5):1785-1797. PubMed ID: 33788346
[TBL] [Abstract][Full Text] [Related]
24. MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance.
Gasparri ML; Besharat ZM; Farooqi AA; Khalid S; Taghavi K; Besharat RA; Sabato C; Papadia A; Panici PB; Mueller MD; Ferretti E
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2313-2318. PubMed ID: 30109500
[TBL] [Abstract][Full Text] [Related]
25. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
[TBL] [Abstract][Full Text] [Related]
26. miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers.
Du L; Subauste MC; DeSevo C; Zhao Z; Baker M; Borkowski R; Schageman JJ; Greer R; Yang CR; Suraokar M; Wistuba II; Gazdar AF; Minna JD; Pertsemlidis A
PLoS One; 2012; 7(6):e39167. PubMed ID: 22723956
[TBL] [Abstract][Full Text] [Related]
27. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma.
Kinose Y; Sawada K; Nakamura K; Sawada I; Toda A; Nakatsuka E; Hashimoto K; Mabuchi S; Takahashi K; Kurachi H; Lengyel E; Kimura T
Oncotarget; 2015 May; 6(13):11342-56. PubMed ID: 25839163
[TBL] [Abstract][Full Text] [Related]
28. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.
Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L
Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN.
Yang H; Kong W; He L; Zhao JJ; O'Donnell JD; Wang J; Wenham RM; Coppola D; Kruk PA; Nicosia SV; Cheng JQ
Cancer Res; 2008 Jan; 68(2):425-33. PubMed ID: 18199536
[TBL] [Abstract][Full Text] [Related]
30. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.
Huh JH; Kim TH; Kim K; Song JA; Jung YJ; Jeong JY; Lee MJ; Kim YK; Lee DH; An HJ
Br J Cancer; 2013 Jul; 109(2):452-61. PubMed ID: 23807165
[TBL] [Abstract][Full Text] [Related]
31. MiR-155-5p exerts tumor-suppressing functions in Wilms tumor by targeting IGF2 via the PI3K signaling pathway.
Luo X; Dong J; He X; Shen L; Long C; Liu F; Liu X; Lin T; He D; Wei G
Biomed Pharmacother; 2020 May; 125():109880. PubMed ID: 32004974
[TBL] [Abstract][Full Text] [Related]
32. miR-296-3p Negatively Regulated by Nicotine Stimulates Cytoplasmic Translocation of c-Myc via MK2 to Suppress Chemotherapy Resistance.
Deng X; Liu Z; Liu X; Fu Q; Deng T; Lu J; Liu Y; Liang Z; Jiang Q; Cheng C; Fang W
Mol Ther; 2018 Apr; 26(4):1066-1081. PubMed ID: 29525743
[TBL] [Abstract][Full Text] [Related]
33. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
35. Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer.
Xue B; Li S; Jin X; Liu L
BMC Cancer; 2021 Apr; 21(1):452. PubMed ID: 33892654
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA profiling reveals dysregulated microRNAs and their target gene regulatory networks in cemento-ossifying fibroma.
Pereira TDSF; Brito JAR; Guimarães ALS; Gomes CC; de Lacerda JCT; de Castro WH; Coimbra RS; Diniz MG; Gomez RS
J Oral Pathol Med; 2018 Jan; 47(1):78-85. PubMed ID: 29032608
[TBL] [Abstract][Full Text] [Related]
37. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
[TBL] [Abstract][Full Text] [Related]
38. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
39. MiR-141-3p is upregulated in esophageal squamous cell carcinoma and targets pleckstrin homology domain leucine-rich repeat protein phosphatase-2, a negative regulator of the PI3K/AKT pathway.
Ishibashi O; Akagi I; Ogawa Y; Inui T
Biochem Biophys Res Commun; 2018 Jun; 501(2):507-513. PubMed ID: 29738771
[TBL] [Abstract][Full Text] [Related]
40. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
